Clinical Behavior of Stage II-IV Low-Grade Serous Carcinoma of the Ovary

Gershenson, David M.; Sun, Charlotte C.; Lu, Karen H.; Coleman, Robert L.; Sood, Anil K.; Malpica, Anaís; Deavers, Michael T.; Silva, Elvio G.; Bodurka, Diane C.

doi:10.1097/01.aog.0000227787.24587.d1

Cited by 253 publications

(222 citation statements)

References 34 publications

Supporting

Mentioning

207

Contrasting

Unclassified

Order By: Relevance

“…Overall survival rates for the two types differ dramatically, with median survival being 82 months [4] versus 30 months [5] for Types I and II, respectively. This difference is despite the initial sensitivity of type II tumours to standard carboplatin and paclitaxel chemotherapy.…”

Section: Classification Of Eocmentioning

confidence: 97%

The Therapeutic Potential of Targeting the HGF/cMET Axis in Ovarian Cancer

Moran-Jones

2016

Mol Diagn Ther

View full text Add to dashboard Cite

Survival rates for ovarian cancer have remained relatively stable for the past two decades, despite advances in surgical techniques and cytotoxic chemotherapeutics, indicating a requirement for better therapies. One pathway currently proposed for targeting is the HGF/cMET pathway. Up-regulated in a number of tumour types, cMET is a tyrosine kinase receptor expressed on epithelial cells. In ovarian cancer, it has been identified as highly expressed in the four major subtypes, with expression estimates ranging from 11-68% of cases. HGF, the only known ligand for cMET, is found at high levels in both serum and ascites in women with ovarian cancer, and proposed to induce both migration and metastasis. However, clinically validated biomarkers are not yet available for either HGF or cMET, preventing a clear understanding of the true rate of over-expression, or its correlation with prognosis.

show abstract

Section: Classification Of Eocmentioning

confidence: 97%

The Therapeutic Potential of Targeting the HGF/cMET Axis in Ovarian Cancer

Moran-Jones

2016

Mol Diagn Ther

View full text Add to dashboard Cite

show abstract

“…The MD Andersen Cancer Centre group went on to describe the clinical features of low-grade serous carcinomas, which include: presenting in younger patients, frequently in high-stage, and showing lower responses to chemotherapy compared with high-grade serous carcinomas. 11 Subsequent studies confirmed that only occasional low-grade serous carcinomas exhibit complete response to standard chemotherapy in the neoadjuvant or recurrent setting. [12][13][14][15] With the increasing evidence suggesting that neoadjuvant chemotherapy is an equivalent or superior treatment regimen for advanced stage ovarian cancer, the selection of cases of patients who are most likely to respond remains a foremost clinical problem, which begins with accurate diagnosis.…”

mentioning

confidence: 93%

The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors

et al. 2013

View full text Add to dashboard Cite

Low-grade serous carcinomas and serous borderline tumors, combined herein and referred to as low-grade serous tumors, show distinct molecular alterations and clinical behaviors compared with high-grade serous carcinomas. The discrimination between low-grade serous tumors and high-grade serous carcinomas can be challenging on small tissue samples, such as cell blocks of paracentesis fluid or biopsies from omental disease. The purpose of this study was to test the ability of TP53 and CDKN2A immunohistochemistry to distinguish between high-grade serous carcinomas and low-grade serous tumors on small tissue samples. Tissue microarrays containing 582 high-grade serous carcinomas, 45 low-grade serous carcinomas, and 49 serous borderline tumors, confirmed by contemporary histopathological review, were stained for TP53 and CDKN2A (DO7 and E6H4 antibody clones, respectively). TP53 was scored as completely absent, wild-type pattern or overexpressed (460%), and CDKN2A was scored as either negative/patchy (o90%) or block expression (490%). The combination of the two markers, ie, the TP53 wild-type pattern and CDKN2A patchy expression, had sensitivity for low-grade serous tumors of 89%, a specificity of 93%, a positive predictive value of 68%, and a negative predictive value of 98%. These markers can, therefore, be used on small biopsies/ cell blocks to refute a diagnosis of low-grade serous tumors. These findings may inform emerging neoadjuvant therapeutic strategies in advanced ovarian cancers and may be crucial for future clinical trials on molecular-based therapies.

show abstract

“…Most patients diagnosed with OC, survival is theorized to be 100%, who are still alive after 5-years, are presumably living with the disease rather than living disease-free. 5 Our analysis demonstrated that the DFS was 18.3 months (10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27). The Surveillance, Epidemiology and End Results-SEER database from 1995 to 2007 with epithelial OC who were actively followed-up and age 20 years or older were included for analyzing OS in the United States (40.692 patients) and OS was 65%, 44%, and 36% at 2, 5, and 10 years, respectively.…”

Section: Discussionmentioning

confidence: 86%

“…Older age at diagnosis was often associated with comorbidities and functional deficits that impact their survival. Gershenson et al 27 reported on a cohort of 112 patients with stage II-IV low-grade serous carcinoma from M.D. Anderson Cancer Center in 2006, and noted age older than 45 years at diagnosis was associated with longer survival.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Factors Affecting Survival in Patients with Ovarian Cancer: A 5-Year Experience in an University Hospital.

Pınar¹

2017

UHOD

View full text Add to dashboard Cite

The aim if this study is to explore the impact of the various prognostic factors on overall survival in women with ovarian cancer (OC). Patients diagnosed with gynecologic malignancy in Gynecology Clinic of Baskent University Medicine Faculty between 2010 and 2015 included to study. Patients with ovarian (n= 112) cancers examined retrospectively. Kaplan-Meier, Univariate and Multivariate Cox regression model were performed to estimate for associations of potential variables with survival factors. The mean patient age was 56.4 y, range 20-80. The overall survival was 94.3%, 83.4%, 66.4%, 54.7% and 42.8% at 1, 2 3, 4 and 5 years respectively (60.5 months, range 43-68). 3-year disease-free survival was 25.3% (18.3 months, range 17-20). Multivariate analysis of patients indicated that stage, histology, grade, age at diagnosis, comorbidity, recurrence, BMI, menopausal status and regional distance were independent prognostic factors on survival (p< 0.05). In conclusion, these results will presents a framework to identify fundamental causes in survival for OC.

show abstract

Clinical Behavior of Stage II-IV Low-Grade Serous Carcinoma of the Ovary

Abstract: Metastatic low-grade serous carcinoma of the ovary is characterized by young age at diagnosis and prolonged overall survival. Segregating women with this diagnosis in future clinical trials is warranted.

Cited by 253 publications

References 34 publications

The Therapeutic Potential of Targeting the HGF/cMET Axis in Ovarian Cancer

The Therapeutic Potential of Targeting the HGF/cMET Axis in Ovarian Cancer

The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors

Prognostic Factors Affecting Survival in Patients with Ovarian Cancer: A 5-Year Experience in an University Hospital.

Contact Info

Product

Resources

About